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Interaction between neuron and microglia has been proved to play critical role in the 1 
mechanism of morphine tolerance, while CXCL10/CXCR3 signaling has been 2 
implicated in neuron-glia signaling and morphine analgesia. This study aims to 3 
investigate whether CXCL10/CXCR3 signaling in periaqueductal gray (PAG) 4 
contributes to the development of morphine tolerance by modulating neuron-microglia 5 
interaction. The results showed that the expressions of CXCR3 and CXCL10 were 6 
gradually increased in parallel with repeated morphine administration and activation of 7 
microglia. CXCR3 was co-localized with neuronal marker NeuN, while CXCL10 was 8 
derived from microglia. Microglia inhibitor minocycline significantly attenuated the 9 
expression of CXCL10, besides, both minocycline and CXCR3 inhibitor alleviated the 10 
development of morphine tolerance. Taken together, our study provided the evidence 11 
that CXCL10/CXCR3 signaling in PAG is involved in the development of morphine 12 
analgesic tolerance via neuron-microglia interaction. 13 
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1. Introduction 5 
Tolerance to morphine-induced antinociceptive effect hinders its prolonged usage in the 6 
clinic. The roles of neuronal intracellular cascades including desensitization of opioid 7 
receptors, endocytosis of opioid receptor and functional changes of glutamate receptors 8 
in the mechanisms of morphine tolerance have been well investigated (Martini and 9 
Whistler, 2007; Tai et al., 2007; Williams et al., 2013). Accumulating evidences 10 
suggest that microglia may play an essential role in the development of morphine 11 
tolerance (Horvath et al., 2010; Wang et al., 2010b; Eidson and Murphy, 2013a). 12 
Microglia could be activated in response to morphine-induced neuronal changes, while 13 
microglia-derived proinflammatory factors including cytokines and chemokines, in turn, 14 
promote the neuronal sensitization (Horvath et al., 2010; Wang et al., 2010b). These 15 
studies indicate the importance of the interaction between neuron and microglia in the 16 
mechanism of morphine tolerance. 17 
Periaqueductal gray (PAG) and its descending projections to rostral ventromedial 18 
medulla and spinal cord comprise an essential neural circuit for opioid-mediated 19 
analgesia (Basbaum and Fields, 1978). Recent studies demonstrated that opioid 20 
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tolerance is accompanied by activation of microglia in PAG (Eidson and Murphy, 1 
2013b), and inhibition of microglia activities could attenuate the development of 2 
morphine tolerance (Eidson and Murphy, 2013a). Although the contribution of 3 
microglia activation in PAG to morphine tolerance has been reported, little is known 4 
about the underlying mechanism of neuron-microglia interaction (Cui et al., 2006). 5 
Chemokines, a family of small cytokines, could directly induce chemotaxis of 6 
responsive cells. Several studies indicate that chemokine receptors, such as CXCR2, 7 
are co-expressed by opioid-containing leukocytes. Inhibiting some chemokines 8 
(CXCL1 and CXCL2/3) could substantially result in the decreased number of opioid-9 
containing immune cells in inflammatory tissue and in consequence abolish the 10 
endogenous peripheral opioid analgesia (Brack et al., 2004; Machelska, 2007), whereas 11 
some chemokines (e.g. CCL5, CXCL12, and CX3CL1) are described to be able to 12 
induce pain or decrease central analgesic effects of opioid receptor agonists in animals 13 
without inflammation (Chen et al., 2007; Oh et al., 2001). Chemokines could also 14 
emerge as potential modulators of neuron-microglia interaction in opioid tolerance-15 
related neuroinflammation and chronic neuropathic pain (Biber et al., 2008; Old and 16 
Malcangio, 2012). The chemokine receptor CXCR3 could be activated by its ligands 17 
including CXCL9, CXCL10 and CXCL11 (Loetscher et al., 1998). Activation of 18 
CXCR3 is involved in NMDA-induced hippocampal cell death (van Weering et al., 19 
2011), entorhinal cortex lesion (Rappert et al., 2004) and brain ischemia (Biber et al., 20 
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2001) by inducing neuron-microglia interaction. Previous study has reported that 1 
CXCL10 was upregulated in nervous system with neuroinflammatory pain (Müller et 2 
al., 2010). Recently, our studies have shown that single morphine administration 3 
promoted CXCL10 expression in spinal neurons, while blocking the function of 4 
CXCL10 could enhance the effect of morphine analgesia in cancer pain animal (Ye et 5 
al., 2014; Bu et al., 2014). In addition, CXCR3 was co-localized with neuron, astrocyte 6 
and microglia in bone cancer pain model (Guan et al., 2015), suggesting 7 
CXCL10/CXCR3-related neuron-microglia interaction may play a critical role in the 8 
formation of bone cancer pain and morphine analgesic effect. Activation of microglia 9 
could be responsible to neuronal changes and aggravate the development of morphine 10 
tolerance by releasing pro-nociceptive factors such as chemokines (Horvath et al., 2010; 11 
Wang et al., 2010b). However, the role of CXCL10/CXCR3 in the morphine tolerance 12 
in PAG remains unclear. Thus, in the present study, we hypothesized that activation of 13 
CXCL10/CXCR3 signaling might participate in the mechanism of morphine tolerance 14 
by modulating neuron-microglia interaction. 15 
 16 
2. Material and methods 17 
2.1. Animals 18 
Adult male Swiss Webster mice, weighing 20-25 g, were purchased from Animal 19 
Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. 20 
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Animals were housed under a 12-hour light/dark cycle at room temperature of 22 ± 1 ℃ 1 
and relative humidity 40-60 % with food and water available ad libitum. The 2 
experimental protocols were reviewed and approved by Institutional Animal Care and 3 
Use Committee of Tongji Medical College of Huazhong University of Science & 4 
Technology. All experimental protocols and animal handling procedures were carried 5 
out in accordance with the National Institutes of Health guidelines for the Care and Use 6 
of Laboratory Animals. 7 
2.2. Drug administration 8 
Animals were anesthetized with pentobarbital sodium (60 mg/kg, intraperitoneally). In 9 
order to facilitate injection, stainless cannula guides (0.60 mm external and 0.35 mm 10 
internal diameters) was implanted unilaterally into dorsal part of PAG (-4.6 mm 11 
posterior to bregma, +/- 0 mm lateral to the midline and -2 mm ventral to the dorsal 12 
surface of the skull) according to the previous study (Masse et al., 2008). A metallic 13 
cannula dummy was placed in the cannula guides after surgery to avoid blood clots. 14 
Animals were allowed a 7-day recovery period before the following experiments. 15 
The following drugs were micro-injected into PAG 30 min before morphine 16 
administration, respectively: CXCR3 inhibitor AMG487 (10 or 20 μg, 0.25 μL, diluted 17 
in 20 % 2-hydroxypropyl-β-cyclodextrin, once daily; Sigma, St. Louis, MO, USA), 18 
microglia inhibitor minocycline (10 pmol, 0.25 μL, diluted in saline, once daily; Sigma, 19 
St. Louis, MO, USA) (Wei et al., 2008; Eidson and Murphy, 2013a), recombinant 20 
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mouse CXCL10 protein (rmCXCL10; 20 μg, 0.25 μL, diluted in saline, once daily; 1 
ProSpec-Tany TechnoGene, Rehovot, Israel). 2 
2.3. Chronic morphine tolerance 3 
To induce chronic morphine tolerance, mice were repeatedly administrated with 4 
morphine subcutaneously (10 mg/kg, twice daily with 12 h intervals), from day 1 (D1) 5 
to day 7 (D7) (Zhou et al., 2010; Ferrini et al., 2013). 6 
2.4. Mechanical nociceptive tests 7 
Nociceptive thresholds of mice were assessed by measuring paw withdrawal thresholds 8 
via von Frey filaments as described previously (Liu et al., 2012; Zhou et al., 2013). 9 
Briefly, behavioral tests were performed on day 0 (D0) and 30 min after morphine 10 
administration from day 1 to day 7. Mice were tested individually in a deep rectangular 11 
stainless-steel tank and allowed 15 minutes for habituation before tests. The region 12 
between foot pads in the plantar aspect of right hind paw was stimulated by a series of 13 
von Frey hairs with logarithmically incrementing forces (0.04, 0.07, 0.16, 0.4. 0.6, 1, 2, 14 
4, 6, 8, 10, 15 and 26 g). Abrupt paw withdrawal, licking, or shaking was considered as 15 
positive responses. Once a withdrawal response was elicited, the test would be repeated 16 
starting with the next descending filament until no response occurred. An interval of 10 17 
seconds was applied between the stimulations of filaments. The lowest amount of force 18 
that elicits a positive response was recorded. Three trials were performed on each 19 
animal with a time interval of 10 minutes, and the average value was considered as the 20 
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paw withdrawal thresholds, represented in grams (g). All behavioral tests were 1 
conducted under blind conditions. 2 
2.5. Real-time Polymerase Chain Reaction 3 
Total RNA was isolated from PAG with Trizol (Invitrogen, Carlsbad, CA). RNA was 4 
used to synthesize cDNA with SuperScript Reverse Transcriptase (Invitrogen, Carlsbad, 5 
CA). Real-time PCR reaction was performed with StepOne Real-time PCR System 6 
(Applied Biosystems) according to the manufacturer’s instructions. Specific primers 7 
for mouse CXCR3 and endogenous control mouse GAPDH were obtained from 8 
PrimerDepot (Table 1). Relative quantification of mRNA was determined by using 2-9 
ΔΔCt method (Schmittgen and Livak, 2008). Data were presented as fold changes 10 
normalized to control group. 11 
2.6. Western blot analysis 12 
Animals were sacrificed and total proteins of PAG tissues were extracted immediately. 13 
The tissues were homogenized in a radio immunoprecipitation assay (RIPA) lysis 14 
buffer (Beyotime, Wuhan, China) containing 1 % Phenylmethanesulfonyl fluoride. The 15 
protein concentration was determined by BCA assay (Boster, Wuhan, China). After 16 
denatured by boiling in a sample buffer, 50 μg proteins from each sample were 17 
separated on SDS polyacrylamide gel and then transferred to polyvinylidene fluoride 18 
membranes (Millipore, Bedford, MA, USA) by electrophoresis. The membranes were 19 
blocked with 5 % non-fat milk in TBST (0.1 % Tween 20 in TBS) for 0.5 hour at room 20 
9 
 
temperature and then incubated with specific primary antibodies (Table 2) overnight at 1 
4 C followed by HRP-conjugated goat anti-rabbit IgG (1: 5000, Boster, Wuhan, China) 2 
or HRP-conjugated goat anti-mouse IgG (1: 1000, Bioyeartech, Wuhan, China) for 2 3 
hours at room temperature in TBS containing 0.05 % Tween-20. Labeled proteins were 4 
then detected by ChemiDocXRS+ chemiluminescence imaging system (Bio-Rad, 5 
Hercules, CA, USA). The protein levels were presented as density relative to that of β-6 
actin. 7 
2.7. Immunofluorescence staining 8 
Mice were anesthetized with pentobarbital sodium and perfused through aortic cannula 9 
with 20 mL of saline, followed with 20 mL of 4 % paraformaldehyde for 20 minutes. 10 
The fixed brains were removed from cranial cavity and post-fixed in the same fixative 11 
solution overnight at 4 C. The tissues were then embedded in paraffin and sections 12 
containing PAG were mounted on slides. Immunofluorescence staining was performed 13 
as previously described (Kong et al., 2013). Briefly, slides were blocked with goat 14 
serum for 60 min, followed by incubation with specific primary antibodies (Table 2) 15 
overnight at 4 C. Then the sections were incubated with DyLight 488-conjugated goat 16 
anti-mouse IgG (1: 100, Abbkine, Inc., Redlands, CA, USA), Cyanine 3 (Cy3)-17 
conjugated goat anti-mouse IgG (1: 200, Abbkine, Inc., Redlands, CA, USA) or 18 
Cyanine 3 (Cy3)-conjugated goat anti-rabbit IgG (1: 200, Abbkine, Inc., Redlands, CA, 19 
USA) for 1 hour at room temperature. Sections were washed with PBST for 10 min and 20 
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mounted in 50% gelvatol (diluted with PBS) for microscopic imaging. Fluorescent 1 
images were captured using a fluorescence microscope (Leica, German). 2 
2.8. Statistical analysis 3 
All data were presented as mean ± SEM. Multiple comparisons were analyzed using 4 
one-way ANOVA followed by Bonferroni’s multiple comparison tests. Data collected 5 
from paw withdrawal thresholds tests were analyzed by using a repeated measures two-6 
way ANOVA followed by Bonferroni’s post-hoc test. P ˂ 0.05 was considered to be 7 
statistically significant difference. 8 
 9 
3. Results 10 
3.1. CXCR3 expression in PAG was gradually increased during the development 11 
of morphine tolerance 12 
We first examined whether morphine tolerance was successfully established after 13 
repeated morphine administration (10 mg/kg, twice daily, s.c.). The results of 14 
behavioral tests showed that paw withdrawal thresholds of morphine-treated mice 15 
decreased dramatically on day 4 as shown in Fig. 1A (F(1,72) = 35.53, P < 0.05). We 16 
then sought to investigate the time course of CXCR3 expression in PAG during the 17 
development of morphine tolerance. As shown in Fig. 1B and 1C, both the expressions 18 
of CXCR3 mRNA and protein were gradually increased along with repeated morphine 19 
administration when compared with baseline (P < 0.01). CXCR3 immunoreactivity in 20 
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PAG in morphine-treated mouse was co-localized with neuronal marker NeuN, but not 1 
with microglial marker Iba-1 or astrocytic marker GFAP (Fig. 1D), indicating that 2 
CXCR3 expressions are increased in neurons in PAG. 3 
 4 
3.2. Repeated administration of morphine increased the expression of CXCL10 5 
derived from microglia 6 
CXCL10 is one of the ligands of CXCR3 and spinal CXCL10 has been shown to be 7 
associated with morphine antinociceptive effect (Harris et al., 2012), therefore, we 8 
detected the expression of CXCL10 in PAG after repeated morphine administration. 9 
The results showed that levels of CXCL10 were increased on day 3 and day 7 in 10 
morphine-treated mice when compared with those in saline-treated mice (Fig. 2A). 11 
CXCL10 immunoreactivities were predominantly co-localized with microglia marker 12 
Iba-1 in morphine-treated mice (Fig. 2B), indicating that microglia may be the major 13 
cellular source of CXCL10 in PAG. The densities of Iba-1 positive microglia in 14 
morphine-treated mice were also increased on day 5 and day 7 when compared with 15 
baseline (P < 0.01) (Fig. 2C and 2D). 16 
 17 
3.3. The development of morphine tolerance was attenuated by inhibition of 18 
CXCR3 activation and promoted by exogenous CXCL10 19 
To determine whether CXCR3 is involved in the development of morphine tolerance 20 
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directly, the CXCR3 inhibitor AMG487 or rmCXCL10 was micro-injected into PAG 1 
30 min before morphine administration, respectively. As shown in Fig. 3A, a single 2 
dose of AMG487 (10 or 20 μg) did not affect the antinociceptive effect of morphine on 3 
the 1st day of morphine administration (P > 0.05), but consecutive treatments with 4 
AMG487 attenuated the development of morphine tolerance (F(2,72) = 34.65 for 5 
AMG487 10 ug/day; F(2,72) = 26.13 for AMG487 20 ug/day, P < 0.05), indicating that 6 
activation of CXCR3 is required for the development of drug tolerance. Administration 7 
of rmCXCL10 (20 μg) could weaken morphine analgesic effect and promote the 8 
formation of morphine tolerance (F(2,72) = 103.1, P < 0.05), which could be prevented 9 
by co-administration with AMG487 (F(3,144) = 64.64, P < 0.05) (Fig. 3B). These findings 10 
demonstrate that CXCL10 and CXCR3 are involved in the development of morphine 11 
tolerance. 12 
 13 
3.4. Inhibition of microglia attenuated the expression of CXCL10 and the 14 
development of morphine tolerance 15 
To verify that microglia-derived CXCL10 is involved in the development of morphine 16 
tolerance, microglia inhibitor minocycline (Tikka et al., 2001), was intra-PAG injected 17 
to inhibit the activation of microglia (Eidson and Murphy, 2013a). The results showed 18 
that pre-treatment with minocycline (10 pmol) could prevent the development of 19 
morphine tolerance (F(2,72) = 42.38, P ˂ 0.05) and co-administration with rmCXCL10 20 
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could reverse the effect of minocycline (F(3,144) = 28.17, P < 0.05) (Fig. 4A). 1 
Minocycline could down-regulate the expression of CXCL10 induced by repeated 2 
morphine treatment (P < 0.01) (Fig. 4B). Proliferation of microglia was observed in 3 
PAG during the development of morphine tolerance, however, it was inhibited by pre-4 
treatment of minocycline, but not affected by AMG487 or rmCXCL10 (P < 0.01) (Fig. 5 
4C and 4D). Increased expression of CXCR3 which was induced by morphine was 6 
attenuated by AMG487 (P < 0.01) but not by minocycline (P > 0.05) (Fig. 4E). These 7 
results provide promising evidences that activation of microglia in PAG contributes to 8 
the development of morphine tolerance may partially through increasing CXCL10 9 
expression, which might be directly correlated with the up-regulation of microglia 10 
activity during the development of morphine tolerance, however microglia-derived 11 
CXCL10 does not affect the activity of microglia and the expression of CXCR3. 12 
 13 
4. Discussion 14 
Our study demonstrated the potential role of microglial CXCL10-neuronal CXCR3 15 
interaction in PAG in the development of morphine tolerance. On the one hand, 16 
repeated morphine treatment up-regulated the expression of CXCR3. Importantly, 17 
blocking CXCR3 slowed the development of morphine tolerance. On the other hand, 18 
morphine treatment was associated with microglia activation and subsequently 19 
increased expression of CXCL10. Inhibition of microglia activation down-regulated 20 
14 
 
CXCL10 expression and consequently prevented the development of morphine 1 
tolerance. Taken together, microglia-derived CXCL10 acts on neuronal CXCR3 2 
receptor, which contributed to the development of morphine tolerance in PAG. 3 
Chronic morphine administration induces the activation of microglia, which increases 4 
the glia-released cytokines including chemokine (Johnston et al., 2004), tumor necrosis 5 
factor alpha (TNF-α) and interleukin-1 beta (IL-1β), resulting in the down-regulation 6 
of astrocytic glutamate transports proteins (GLT-1, GLAST) (Watkins et al., 2009) and 7 
neuronal GABA (gamma-aminobutyric acid) receptors (Stellwagen et al., 2005). 8 
Several studies have reported that morphine binds to neuronal mu opioid receptors in 9 
PAG which are primarily located in GABAergic neurons (Chieng & Christie, 1994; 10 
Commons et al., 2000). These microglia-related cytokines could induce the intracellular 11 
changes, such as the activities of mu opioid receptors in GABAergic neurons, and 12 
effectively increase the neuronal excitability that may contribute to the development of 13 
morphine tolerance. CXCR3 signaling usually functions in chemotaxis and 14 
inflammatory responses in lymphocytes or inflammatory cells under various 15 
pathological conditions (Agostini et al., 2001; Sorensen et al., 2002; Wenzel et al., 16 
2007). Moreover, it was shown to mediate neuron-microglia interaction in acute brain 17 
injury and ischemia (Biber et al., 2001; Rappert et al., 2004; van Weering et al., 2011). 18 
The expressions and functions of CXCR3 in neurons (Xia et al., 2000), microglia 19 
(Rappert et al., 2004) and astrocytes (Tanuma et al., 2006) in various animal models 20 
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have been reported previously, but the cellular localization in PAG is still unknown. 1 
Our results found that the expression of CXCR3 in PAG was increased during the 2 
development of morphine tolerance, and CXCR3 was expressed in neurons, but not in 3 
glia. Moreover, blocking CXCR3 with its antagonist effectively prevented the 4 
development of morphine tolerance. These findings provide definitive evidences that 5 
neuronal chemokine receptor in PAG plays a critical role in the mechanism of morphine 6 
tolerance. 7 
It has been reported that CXCL10 in spinal cord modulated morphine antinociceptive 8 
effect through CXCR3 signaling (Ye et al., 2014). The function and expression of 9 
CXCL10 have been demonstrated in microglia (Shen et al., 2006), neurons (Sui et al., 10 
2006) and astrocytes (Sanchez-Blazquez et al., 2008) in in vitro studies. However, the 11 
types of neural cells which could express CXCL10 are various under different 12 
pathological conditions (Tanuma et al., 2006; van Weering et al., 2011). Our results 13 
showed that increased CXCL10 expression in PAG induced by morphine treatment was 14 
localized in microglia, but not in neurons or astrocytes. Interestingly, microglia 15 
chemotactic activation was found to be down-regulated by the activation of mu opioid 16 
receptors (Chao et al., 1997), which means that the activity of microglia chemotaxis 17 
could be encouraged by desensitization of mu opioid receptor after repeated morphine 18 
stimulation. Consistent with this finding, the increased expression of CXCL10 was 19 
parallel with the development of morphine tolerance, and inhibiting microglia 20 
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activation with minocycline could not only down-regulate CXCL10 expression in 1 
microglia, but also prevent the development of morphine tolerance. These results 2 
suggested that activated microglia participate in the development of morphine tolerance 3 
by releasing CXCL10 which could activate CXCR3 and then might induce the cellular 4 
changes of signal transduction in neurons in PAG. Besides this study, most studies have 5 
identified that inhibiting microglia could attenuate the development of morphine 6 
tolerance (Wang et al., 2010b; Wen et al., 2011). However, a recent study reported that 7 
intra-PAG treatment with minocycline was not sufficient to attenuate morphine 8 
tolerance (Eidson and Murphy, 2013a). The reason for this discrepancy might be the 9 
different usage of minocycline in the experimental protocols. In the study of Edison LN 10 
et al., minocycline was only used in the early phase of the development of morphine 11 
tolerance (from day 1 to day 3 of morphine injection). Nevertheless, the inhibitory 12 
effect of minocycline on the formation of morphine tolerance was not observed until 13 
day 4 of morphine injection in our study, which suggests that microglia may play a role 14 
in the development of drug tolerance rather than analgesic effect of single 15 
administration of morphine. Taken together, our results indicate that CXCL10/CXCR3 16 
signaling in PAG may contribute to the development of morphine tolerance by 17 
mediating neuron-microglia interaction.  18 
When morphine binds to mu opioid receptor (MOR), multiple intracellular downstream 19 
pathways could be activated. The Gα and Gβγ subunits dissociate from one another, 20 
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which subsequently lead to the inhibition of cyclic-adenosine monophosphate (cAMP) 1 
formation and calcium conductance to produce the analgesic effect (Ingram and 2 
Williams, 1994; Schroeder et al, 1991). Previous study showed that inhibiting Gi 3 
protein could partially block the algesia induced by CXCL10, indicating that Gi protein 4 
is involved in the nociceptive signaling pathway related to CXCR3 (Ye et al, 2014). In 5 
the present study, our results suggested that CXCL10 and its receptor CXCR3 are 6 
involved in the development of morphine analgesic tolerance via neuron-microglia 7 
interaction in PAG. However, there is still lack of direct evidence to elucidate the 8 
mechanism of CXCL10/CXCR3 downstream signaling that may contribute to the 9 
development of morphine tolerance. Activation of several kinase transcription factor 10 
cascades may be required to mediate morphine tolerance, including 11 
calcium/calmodulin-dependent protein kinase II (CaMKII) and cAMP response 12 
element-binding protein (CREB) in neurons and p38 and nuclear factor kappa B (NFκB) 13 
in microglia because inhibitors of CaMKII and p38 pathways could reduce the increases 14 
of phosphorylated CREB and acetylated-NFκB levels and attenuate the development of 15 
tolerance (Ammon-Treiber and Hollt, 2005; He et al., 2009; Sanchez-Blazquez et al., 16 
2008; Wang and Burns, 2009; Wang et al., 2010a; Wang et al., 2010b; Wang et al., 17 
2011). Chronic CXCL10 exposure could increase the phosphorylation of CREB in 18 
cultured hippocampal neurons (Bajova et al., 2008), suggesting that the activation of 19 
neuronal CXCR3 induced by microglial CXCL10 may play a key role in the 20 
18 
 
development of morphine tolerance through CaMKII/CREB signaling. In addition, 1 
p38MAPK has also been shown to participate in neuronal CREB phosphorylation 2 
(Freeland et al., 2000; Ma et al., 2001) and contribute to the development of morphine 3 
tolerance by facilitating microglia activation in spinal cord (Cui et al., 2006; Cui et al., 4 
2008). Although detailed signaling pathways of CXCL10/CXCR3 associated with 5 
morphine analgesic tolerance have not yet been studied, some kinases related to other 6 
chemokine receptors, such as Src family-kinases which were identified to be involved 7 
in the mechanism of morphine analgesia (Rivat et al, 2014), should be considered in 8 
the further research to explore the intracellular mechanisms triggered by CXCR3 in 9 
morphine tolerance. 10 
 11 
5. Conclusions 12 
In summary, our study provides a novel insight into the roles of CXCL10/CXCR3 in 13 
the development of morphine tolerance in PAG and suggests the beneficial possibility 14 
of restoring morphine antinociceptive effect by inhibiting CXCR3 activation. These 15 
findings thus implicate a new clinical strategy for preventing morphine tolerance and 16 
may contribute to expanding the morphine usage in clinic. 17 
 18 
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Figure 1. 17 
Enhanced expression of CXCR3 in PAG during the development of morphine tolerance. 18 
A. Pain thresholds of mice were assessed using paw withdrawal thresholds to 19 
mechanical pressure. The decreased paw withdrawal thresholds in morphine-treated 20 
32 
 
mice indicated the successful establishment of morphine tolerance. Repeated 1 
measurement two-way ANOVA followed by Bonferroni post-hoc test, * P < 0.05 vs. 2 
saline. n = 7 in each group. B and C. The mRNA and protein levels of CXCR3 were 3 
measured by real-time PCR and western blots, respectively. The expressions of CXCR3 4 
were gradually increased along with repeated morphine administration. One-way 5 
ANOVA followed by Bonferroni post-hoc test, ** P < 0.01 vs. D0. n = 5 in each group. 6 
D. Double immunostaining of CXCR3 and cell-specific markers in PAG. The mergence 7 
showed that CXCR3 was localized in NeuN positive neurons (indicated by arrows). 8 
Scale bars: 100 μm. 9 
 10 
Figure 2. 11 
Repeated morphine treatment increased microglia-derived CXCL10 production in PAG. 12 
A. Western blot analysis showed that repeated morphine treatment increased the 13 
expression of CXCL10 on day 3 and day 7. One-way ANOVA followed by Bonferroni 14 
post-hoc test, * P < 0.05 vs. saline. ** P < 0.01 vs. saline. n = 5 in each group. B. 15 
Double immunostaining of CXCL10 and cell-specific markers in morphine-treated 16 
mice. CXCL10 was localized in Iba-1 positive microglia (indicated by arrows). Scale 17 
bars: 100 μm. C and D. Immunostaining of Iba-1 in morphine-treated mice. The 18 
densities of Iba-1 positive microglia significantly increased along with the development 19 
of morphine tolerance. Scale bars: 100 μm. One-way ANOVA followed by Bonferroni 20 
33 
 
post-hoc test, ** P < 0.01 vs. D0. n = 5 in each group. 1 
 2 
Figure 3.  3 
CXCL10 and CXCR3 participated in the development of morphine tolerance. A. The 4 
decreases of paw withdrawal thresholds in morphine-treated mice were attenuated by 5 
pre-treatment with AMG487 in a dose-related manner. Repeated measurement two-way 6 
ANOVA followed by Bonferroni post-hoc test, * P < 0.05 vs. sham. # P ˂ 0.05 vs. 7 
morphine. n = 7 in each group. B. Pre-treatment with rmCXCL10 could decrease 8 
morphine antinociceptive effect from day 1 to day 3 and accelerate the development of 9 
morphine tolerance in mice, while co-administration of AMG487 could attenuate the 10 
effect of rmCXCL10. Repeated measurement ANOVA followed by Bonferroni post-11 
hoc test, * P < 0.05 vs. sham. # P ˂ 0.05 vs. morphine. n = 7 in each group. 12 
 13 
Figure 4.  14 
Inhibition of microglia activation attenuated CXCL10 expression and morphine 15 
tolerance. A. Intra-PAG treatment of minocycline (10 pmol) 30 min before morphine 16 
injection attenuated the development of morphine tolerance, whereas the effect of 17 
minocycline was inhibited by pre-treatment with rmCXCL10. Repeated measurement 18 
ANOVA followed by Bonferroni post-hoc test, * P < 0.05 vs. morphine. # P < 0.05 vs. 19 
Minocycline + Morphine. n = 7 in each group. B. Western blot analysis showed that 20 
34 
 
morphine treatment could increase CXCL10 expression. Pre-treatment with 1 
minocycline before morphine injection could down-regulate CXCL10 expression. One-2 
way ANOVA followed by Bonferroni post-hoc test, * P < 0.05, ** P < 0.01 vs. saline. 3 
## P ˂ 0.01 vs. Morphine. n = 5 in each group. C and D. Immunostaining of Iba-1 in 4 
PAG. Minocycline could inhibit the expression of Iba-1 and rmCXCL10 could not alter 5 
the effect of minocycline. Scale bars: 100 μm. One-way ANOVA followed by 6 
Bonferroni post-hoc test, ** P < 0.01 vs. saline. ## P < 0.01 vs. Morphine. n = 5 in each 7 
group. E. Western blot analysis showed that morphine-induced CXCR3 expression 8 
could be attenuated by AMG487 but not by minocycline. One-way ANOVA followed 9 
by Bonferroni post-hoc test, ** P ˂ 0.01 vs. saline. ## P ˂ 0.01 vs. Morphine. n = 5 in 10 
each group.   11 
